New Drug Improves Cholesterol, but Doesnt Lower Heart Risks

A Cleveland Clinc study finds that evacetrapib lowers LDL and raises HDL, yet heart attack and stroke rates are unchanged among patients on the drug.

By
estaff
-
Published:
0
Despite its ability to reduce LDL (bad) cholesterol and significantly increase levels of HDL (good) cholesterol, the experimental medication evacetrapib failed to reduce rates of major cardiovascular events, such as heart attack and stroke.
To continue reading this article or issue you must be a paid subscriber. Sign in
Subscribe

Subscribe to Heart Advisor

Get the next year of Heart Advisor for just $20. And access all of our online content - over 2,000 articles - free of charge.
Subscribe today and save 38%. It's like getting 5 months FREE!
Already Subscribed?
Click Here to Sign In | Forgot your password? | Activate Web Access

RELATED ARTICLESMORE FROM AUTHOR